Ocuphire Pharma Basic EPS 2010-2024 | IRD
Ocuphire Pharma basic eps from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| Ocuphire Pharma Annual Basic EPS |
| 2023 |
$-0.46 |
| 2022 |
$0.90 |
| 2021 |
$-3.82 |
| 2020 |
$-5.28 |
| 2019 |
$-2.17 |
| 2018 |
$-21.00 |
| 2017 |
$-44.18 |
| 2016 |
$-20.65 |
| 2015 |
$-37.94 |
| 2014 |
$-52.82 |
| 2013 |
$-33.61 |
| 2012 |
$-28.81 |
| 2011 |
$-57.62 |
| 2010 |
$-86.44 |
| 2009 |
$-24.01 |
| Ocuphire Pharma Quarterly Basic EPS |
| 2024-06-30 |
$-0.30 |
| 2024-03-31 |
$-0.29 |
| 2023-12-31 |
$-0.20 |
| 2023-09-30 |
$0.26 |
| 2023-06-30 |
$-0.24 |
| 2023-03-31 |
$-0.28 |
| 2022-12-31 |
$1.72 |
| 2022-09-30 |
$-0.22 |
| 2022-06-30 |
$-0.25 |
| 2022-03-31 |
$-0.35 |
| 2021-12-31 |
$0.52 |
| 2021-09-30 |
$-0.25 |
| 2021-06-30 |
$-0.52 |
| 2021-03-31 |
$-3.57 |
| 2020-12-31 |
$-3.65 |
| 2020-09-30 |
$-0.33 |
| 2020-06-30 |
$-0.43 |
| 2020-03-31 |
$-0.87 |
| 2019-12-31 |
$4.71 |
| 2019-09-30 |
$-1.96 |
| 2019-06-30 |
$-2.44 |
| 2019-03-31 |
$-2.48 |
| 2018-12-31 |
$-3.96 |
| 2018-09-30 |
$-8.08 |
| 2018-06-30 |
$-5.80 |
| 2018-03-31 |
$-3.16 |
| 2017-12-31 |
$-0.48 |
| 2017-09-30 |
$-1.92 |
| 2017-06-30 |
$1.92 |
| 2017-03-31 |
$-43.70 |
| 2016-12-31 |
$-0.96 |
| 2016-09-30 |
$-6.24 |
| 2016-06-30 |
$-3.84 |
| 2016-03-31 |
$-9.60 |
| 2015-12-31 |
$-9.12 |
| 2015-09-30 |
$-9.60 |
| 2015-06-30 |
$-9.60 |
| 2015-03-31 |
$-9.60 |
| 2014-12-31 |
$-4.80 |
| 2014-09-30 |
$-4.80 |
| 2014-06-30 |
$0.00 |
| 2014-03-31 |
$-43.22 |
| 2013-12-31 |
$-4.80 |
| 2013-09-30 |
$-9.60 |
| 2013-06-30 |
$-14.41 |
| 2013-03-31 |
$-4.80 |
| 2012-12-31 |
$0.00 |
| 2012-09-30 |
$-14.41 |
| 2012-06-30 |
$-4.80 |
| 2012-03-31 |
$-9.60 |
| 2011-12-31 |
$4.80 |
| 2011-09-30 |
$-9.60 |
| 2011-06-30 |
$-28.81 |
| 2011-03-31 |
$-24.01 |
| 2010-12-31 |
$-9.60 |
| 2010-09-30 |
$0.00 |
| 2010-06-30 |
$-24.01 |
| 2010-03-31 |
$-52.82 |
| 2009-12-31 |
$14.41 |
| 2009-09-30 |
$-9.60 |
| 2009-06-30 |
$-14.41 |
| 2009-03-31 |
$-14.41 |
| Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
|
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|
